| Literature DB >> 26805933 |
Jing Lu1, Hao Gu2,3, Qiuqin Tang4, Wei Wu2,3,5, Beilei Yuan2,3, Dan Guo2,3, Yongyue Wei6, Hong Sun7, Yankai Xia2,3, Hongjuan Ding4, Lingqing Hu5, Daozhen Chen5, Jiahao Sha8, Xinru Wang2,3.
Abstract
MicroRNA plays an important role in spermatogenesis. Whether pre-miRNAs polymorphisms are associated with idiopathic male infertility remains obscure. In this study, 1378 idiopathic infertile males and 486 fertile controls were included between 2006 and 2014. Genotype of three polymorphisms (hsa-mir-146a rs2910164, hsa-mir-196a-2 rs11614913, and hsa-mir-499 rs3746444) and expression of miRNA in seminal plasma were examined by TaqMan method. The role of hsa-miR-196a-5p in cell proliferation, apoptosis and cell cycle were also examined in GC-2 cells. Our results demonstrated that rs11614913 of hsa-miR-196a-2 was significantly associated with idiopathic infertility (TT vs. CT: P = 0.014; TT vs. CC: P = 0.005; TT vs. CT + CC: P = 0.003). In following stratified analysis, we found that rs11614913 exhibited a significantly higher risk of asthenospermia, oligozoospermia and azoospermia. However, no significant association was observed between the other two polymorphisms and idiopathic male infertility risk. In a genotype-expression correlation analysis, rs11614913 CC was significantly associated with elevated expression of hsa-miR-196a-5p (P < 0.05). Additionally, apoptosis levels were significantly increased in hsa-miR-196a-5p mimic treated GC-2 cells, while decreased in hsa-miR-196a-5p inhibitor treated GC-2 cells. Our data revealed a significant relationship between hsa-miR-196a-2 polymorphism and idiopathic male infertility.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26805933 PMCID: PMC4726409 DOI: 10.1038/srep19825
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Characteristics of the control and case.
| Variables | Control | Case | Normospermia | Asthenospermia | Oligozoospermia | Azoospermia |
|---|---|---|---|---|---|---|
| Total | ||||||
| (n = 486) | (n = 1378) | (n = 927) | (n = 405) | (n = 131) | (n = 140) | |
| Age (years, mean ± SD) | 29.66 ± 3.11 | 28.86 ± 4.09* | 28.68 ± 4.12* | 29.21 ± 3.98 | 28.78 ± 3.90* | 29.31 ± 4.67 |
| BMI (kg/m2, mean ± SD)e | 23.86 ± 2.62 | 23.58 ± 3.01 | 23.54 ± 2.84* | 23.81 ± 3.43 | 23.54 ± 4.40 | 23.91 ± 2.79 |
| Smoking status [n (%)] | ||||||
| No | 310 (63.79) | 779 (56.53) | 518 (55.88) | 236 (58.27) | 69 (52.67) | 73 (52.14) |
| Yes | 176 (36.21) | 599 (43.47)* | 409 (44.12)* | 169 (41.73) | 62 (47.33)* | 67 (47.86)* |
| Alcohol intake [n (%)] | ||||||
| No | 436 (90.12) | 1197 (86.87) | 794 (85.65) | 362 (89.38) | 116 (88.55) | 129 (92.14) |
| Yes | 48 (9.88) | 181 (13.13) | 133 (14.35)* | 43 (10.62) | 15 (11.45) | 11(7.86) |
| Abstinence time (days, mean ± SD) | 4.47 ± 1.70 | 5.43 ± 3.53* | 5.47 ± 3.26* | 5.46 ± 3.91* | 4.75 ±1.78 | 5.68 ± 2.91* |
| Ejaculate volume (ml, mean ± SD) | 3.29 ± 1.13 | 3.00 ± 1.46* | 3.26 ± 1.49 | 2.70 ± 1.29* | 3.04 ± 1.54 | 2.39 ± 1.22* |
aSubjects with normal sperm concentration and motility.
bSubjects with sperm motility < 32%.
cSubjects with sperm concentration < 15 × 106/ml.
dSubjects with sperm concentration = 0 × 106/ml.
eBMI: body mass index.
*P < 0.05 for T test or two-side X2 test for selected characteristics distributions between control and case groups.
Associations of three pre-miRNA polymorphisms with risk of idiopathic asthenospermia, oligozoospermia and azoospermia.
| Control | Case | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (n = 486) | Total (n = 1378) | Normospermiaa(n = 927) | Asthenospermia | Oligozoospermi | Azoospermia | |||||||||||
| n (%) | n (%) | OR (95% CI) | n (%) | OR (95% CI) | n (%) | OR (95% CI) | n (%) | OR (95% CI) | n (%) | OR (95% CI) | ||||||
| TT | 186 (38.27) | 424 (30.77) | 1.00 (Ref.) | 313 (33.76) | 1.00 (Ref.) | 102 (25.19) | 1.00 (Ref.) | 26 (19.85) | 1.00 (Ref.) | 36 (25.71) | 1.00 (Ref.) | |||||
| CT | 213 (43.83) | 656 (47.61) | 427 (46.06) | 1.17 (0.92–1.51) | 0.204 | 209 (51.60) | 59 (45.04) | 68 (48.57) | ||||||||
| CC | 87 (17.90) | 298 (21.63) | 187 (20.17) | 1.31 (0.95–1.79) | 0.098 | 94 (23.21) | 46 (35.11) | 36 (25.71) | ||||||||
| CT + CC | 300 (61.73) | 954 (69.23) | 614 (66.23) | 1.21 (0.96–1.53) | 0.102 | 303 (74.81) | 105 (80.15) | 104 (74.28) | ||||||||
| CC | 92 (18.93) | 248 (18.00) | 1.00 (Ref.) | 157 (16.94) | 1.00 (Ref.) | 80 (19.75) | 1.00 (Ref.) | 28 (21.37) | 1.00 (Ref.) | 26 (18.57) | 1.00 (Ref.) | |||||
| CG | 204 (41.98) | 656 (47.61) | 1.19 (0.89–1.59) | 0.238 | 443 (47.79) | 1.27 (0.93–1.73) | 0.129 | 192 (47.41) | 1.09 (0.76–1.57) | 0.633 | 61 (46.56) | 0.97 (0.58–1.63) | 0.917 | 73 (52.14) | 1.26 (0.75–2.11) | 0.374 |
| GG | 190 (39.09) | 474 (34.40) | 0.94 (0.70–1.26) | 0.674 | 327 (35.28) | 1.03 (0.75–1.41) | 0.869 | 133 (32.84) | 0.81 (0.56–1.18) | 0.273 | 42 (32.06) | 0.73 (0.42–1.26) | 0.256 | 41 (29.29) | 0.75 (0.43–1.31) | 0.320 |
| CG + GG | 394 (81.07) | 1130 (82.01) | 1.07 (0.82–1.40) | 0.627 | 770 (83.06) | 1.15 (0.86–1.54) | 0.330 | 325 (80.25) | 0.95 (0.68–1.34) | 0.790 | 103 (78.63) | 0.85 (0.53–1.38) | 0.524 | 114 (81.43) | 1.02 (0.63–1.66) | 0.943 |
| AA | 340 (69.96) | 989 (71.77) | 1.00 (Ref.) | 663 (71.52) | 1.00 (Ref.) | 296 (73.09) | 1.00 (Ref.) | 94 (71.76) | 1.00 (Ref.) | 95 (67.86) | 1.00 (Ref.) | |||||
| AG | 132 (27.16) | 351 (25.47) | 0.91 (0.72–1.16) | 0.443 | 236 (25.46) | 0.90 (0.70–1.16) | 0.404 | 101 (24.94) | 0.89 (0.66–1.21) | 0.460 | 33 (25.19) | 0.94 (0.60–1.47) | 0.781 | 41 (29.29) | 1.13 (0.74–1.72) | 0.566 |
| GG | 14 (2.88) | 38 (2.76) | 0.93 (0.49–1.74) | 0.811 | 28 (3.02) | 0.99 (0.51–1.91) | 0.967 | 8 (1.98) | 0.66 (0.27–1.61) | 0.363 | 4 (3.05) | 1.25 (0.39–3.95) | 0.708 | 4 (2.86) | 1.00 (0.32–3.14) | 0.999 |
| AG + GG | 146 (30.04) | 389 (28.23) | 0.91 (0.73–1.15) | 0.434 | 264 (28.48) | 0.91 (0.71–1.16) | 0.429 | 109 (26.91) | 0.87 (0.65–1.17) | 0.353 | 37 (28.24) | 0.96 (0.62–1.49) | 0.868 | 45 (32.14) | 1.12 (0.74–1.68) | 0.591 |
OR, odds ratios; CI, confidence interval;
aSubjects with normal sperm concentration and motility.
bSubjects with sperm motility < 32%.
cSubjects with sperm concentration < 15 × 106/ml.
dSubjects with sperm concentration = 0 × 106/ml.
ORs were adjusted for age, BMI, smoking status and alcohol drinking.
Figure 1Expression level of hsa-miR-196a-5p in seminal plasma of idiopathic infertile males and fertile controls with different genotypes of rs11614913.
(A) Expression level of hsa-miR-196a-5p in idiopathic infertile males and fertile controls (n = 80 for fertile controls; n = 107 for idiopathic infertile males). (B) Expression level of hsa-miR-196a-5p in fertile controls with different genotypes (n = 37 for TT genotype; n = 29 for CT genotype; n = 14 for CC genotype). (C) Expression level of hsa-miR-196a-5p in idiopathic infertile males with different genotypes (n = 35 for TT genotype; n = 49 for CT genotype; n = 25 for CC genotype). Data are shown as mean ± SEM in each group. Statistical analyses for hsa-miR-196a-5p expression level were performed by Mann-Whitney test. Significant difference is marked with *P < 0.05.
Figure 2The role of hsa-miR-196a-5p in cell proliferation, apoptosis and cycle cycle in vitro.
(A) The role of hsa-miR-196a-5p in cell proliferation. An MTT cell viability assay was performed at 24 h after the transfection of GC-2 cells with equal concentrations of hsa-miR-196a-5p mimics and hsa-miR-196a-5p inhibitor. (B) The role of hsa-miR-196a-5p in cell apoptosis. (C) The role of hsa-miR-196a-5p in cell cycle. For comparison, the expression levels of hsa-miR-196a-5p mimics or hsa-miR-196a-5p inhibitor transfected cells were compared with their respective negative controls (*P < 0.05).